Fiduciary Group LLC Has $3.34 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Fiduciary Group LLC lifted its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,912 shares of the company's stock after buying an additional 3,917 shares during the period. Fiduciary Group LLC's holdings in AstraZeneca were worth $3,336,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Albion Financial Group UT grew its stake in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after buying an additional 248 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of AstraZeneca by 2,618.5% in the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company's stock worth $48,000 after acquiring an additional 707 shares in the last quarter. Golden State Wealth Management LLC bought a new stake in AstraZeneca during the 4th quarter worth approximately $55,000. Crews Bank & Trust acquired a new stake in AstraZeneca during the 4th quarter valued at $55,000. Finally, Newbridge Financial Services Group Inc. bought a new position in AstraZeneca in the 4th quarter valued at $55,000. Institutional investors own 20.35% of the company's stock.

AstraZeneca Trading Down 1.1 %

NASDAQ:AZN traded down $0.84 on Monday, hitting $74.09. 3,740,890 shares of the stock were exchanged, compared to its average volume of 4,936,571. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a 52 week low of $62.75 and a 52 week high of $87.68. The stock has a market capitalization of $229.77 billion, a price-to-earnings ratio of 32.78, a P/E/G ratio of 1.42 and a beta of 0.41. The company's 50-day moving average price is $72.83 and its 200 day moving average price is $71.91.

Remove Ads

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. On average, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be given a $1.03 dividend. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. The ex-dividend date is Friday, February 21st. AstraZeneca's dividend payout ratio (DPR) is currently 91.15%.

Analyst Ratings Changes

AZN has been the topic of several research analyst reports. Morgan Stanley began coverage on AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of "Buy" and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.